Saturday, 3 October 2026European Markets

Euro Surges 14% Against Dollar as US Currency Hits 2022 Lows

The euro has gained 14% against the US dollar in 2025, while the British pound climbed 7%, as the greenback fell to its lowest level since 2022. The dollar's weakness stems from uncertainty ahead of Jerome Powell's June 2026 Federal Reserve departure and shifting investor sentiment toward European currencies.

Euro Surges 14% Against Dollar as US Currency Hits 2022 Lows
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The euro traded 14% higher against the US dollar in 2025, marking the greenback's steepest decline since 2022. The British pound gained 7% over the same period, reflecting a broad shift away from dollar-denominated assets.

Market uncertainty around the June 2026 Federal Reserve chair transition from Jerome Powell has weakened dollar confidence. Geopolitical developments, including progress on Iran-US nuclear negotiations, have accelerated the currency rotation.

European investors face new opportunities as dollar weakness makes US assets cheaper. American stocks, bonds, and real estate now cost 14% less in euro terms than at the start of 2025. European companies with US revenue streams see higher euro-equivalent earnings on repatriation.

The shift benefits European exporters to the United States. German manufacturers and French luxury brands gain pricing power as their products become more competitive against US-produced alternatives. Tourism sectors across Spain, Italy, and Greece expect increased American visitor spending.

Currency analysts warn the dollar's decline may reach limits soon. Jordan Rochester at Mizuho Bank forecasts potential GBP reversal below $1.30 as the UK Budget and Fed leadership change approach. Simon Phillips at No1 Currency noted pressure on sterling despite recent gains.

European bond markets have strengthened alongside currency gains. The euro's rise makes European government debt more attractive to international investors seeking alternatives to US Treasuries. UK gilt auctions drew record demand, with £69 billion in bids for £4.25 billion in inflation-linked bonds.

Strategic investors should consider US dollar exposure while valuations favor euro-based buyers. Technology stocks trading on US exchanges offer entry points 14% below year-start euro prices. Real estate investment trusts and corporate bonds present similar opportunities.

The currency shift also carries risks. A sudden dollar rebound would reduce gains on US holdings. European Central Bank policy decisions and eurozone economic data will determine whether the euro maintains its strength through year-end.

Market sentiment currently favors non-dollar currencies, but analysts caution against assuming permanent trends. Fed policy clarity following the 2026 chair transition could restore dollar demand.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com